Verification of Harmonization of Plasma Epstein-Barr Virus DNA Measurements
NCT ID: NCT05037357
Last Updated: 2022-07-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
370 participants
OBSERVATIONAL
2021-08-01
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Plasma EBV DNA Monitoring in Post-treatment NPC Patients
NCT03973723
Reproducibility and Reliability of Epstein-Barr Virus (EBV) DNA/RNA Measures in Nasopharyngeal Swabs
NCT01972815
Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
NCT06445088
Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas
NCT06870435
Effect of the Plasma EBV DNA Change During Chemoradiotherapy in Nasopharyngeal Carcinoma
NCT03087695
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
nasopharyngeal carcinoma patients
Plasma EBV DNA quantification by quantitative polymerase chain reaction (qPCR) assays in different medical centers.
Plasma EBV DNA qPCR test
Peripheral blood will be collected from each subject into an EDTA tube for the isolation of plasma.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Plasma EBV DNA qPCR test
Peripheral blood will be collected from each subject into an EDTA tube for the isolation of plasma.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed NPC or Non-NPC with positive plasma cell-free EBV DNA
Exclusion Criteria
* Any severe intercurrent disease
* Any contraindication of blood sampling
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wuzhou Red Cross Hospital
OTHER
Zhongshan People's Hospital, Guangdong, China
OTHER
Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ming-Yuan Chen
professor & chief physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ming-Yuan Chen, MD, PhD
Role: STUDY_CHAIR
Sun Yat-sen University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SYSUCC-CMY-2021-EBV
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.